A comparison of leflunomide and subcutaneous methotrexate in the treatment of rheumatoid arthritis: an approximation based on the number needed to treat;Comparación de leflunomida y metotrexato subcutáneo en el tratamiento de la artritis reumatoide: una aproximación basada en el número de pacientes que es necesario tratar

Reumatologia Clinica

Volumn 5, Issue 2, 2009, Pages 66-70

  García Ruiz, Antonio J ^a   Montesinos Gálvez, Ana C ^a   Pérez Costillas, Lucía ^a   Rebollo, Pablo ^b  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b BAP Health Outcomes Research   (Spain)

Author keywords

Cost; NNT; Pharmacoeconomics; Rheumatoid arthritis; Treatment

Indexed keywords

LEFLUNOMIDE; METHOTREXATE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

EID: 62349115205     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2008.11.001     Document Type: Article

References (21)

1. Carmona L., Villaverde V., Hernández C., Ballina J., Gabriel R., Laffón A., and the EPISER study group. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology 41 (2002) 88-95
2. Carmona L. Epidemiología de la artritis reumatoide. Rev Esp Reumatol 29 (2002) 86-89
3. Gómez Rodríguez N. Repercusión socioeconómica de la artritis reumatoide. An Med Interna (Madrid) 20 (2003) 111-113
4. Strand V., Cohen S., Schiff M., Weaver A., Fleischmann R., Cannon G., et al., Leflunomide Rheumatoid Artritis Investigators Group. Treatment of active rheumatoid artritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 159 (1999) 2542-2550
5. Felson D.T., Anderson J.J., Boers M., Bombardier C., Furst D., Godsmith C., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995) 727-735
6. Emery P., Breedveld F.C., Lemmel E.M., Kaltwasser J.P., Dawes P.T., Gömör B., et al., Leflunomide Rheumatoid Artritis Investigators Group. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39 (2000) 655-665
7. Comité de Especialidades farmacéuticas. Informe europeo público de evaluación (EPAR) [citado 8 Feb 2007]. London: EMEA. Disponible en: http://www.emea.eu.int/humandocs/PDFs/EPAR/Arava/169499es1.pdf
8. Schádlich P.K., Zeidler H., Zink A., Grommica-Ihle E., Schneider M., Straub C., et al. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for Rheumatoid Arthritis in Germany. Pharmacoeconomics 23 (2005) 395-420
9. Wegrzyn J., Adeleine P., and Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 63 (2004) 1232-1234
10. Moitra R.K., Ledingham J.M., Hull R.G., McCrae F.C., Thomas A.L., Shaban R., et al. Caveats to the use of parenteral methotrexate in the treatment of rheumatic disease. Rheumatology 44 (2005) 256-257
11. Bingham S.J., Buch M.H., Lindsay S., Pollard A., White J., and Emery P. Parenteral methotrexate should be given before biological therapy. Rheumatology 42 (2003) 1009-1010
12. Abraira V. Medidas del efecto de un tratamiento (II): odds ratio y número necesario para tratar. SEMERGEN 27 (2001) 418-420
13. Fichas técnicas de Producto: Ministerio de Sanidad y Consumo (Madrid) [citado 8 Feb 2007]. Disponible en: http://www.agemed.es/
14. Vademecum Internacional (en línea) [citado 8 Feb 2007]. Madrid: CMP MEDICOM; 2007. Disponible en: http://www.vademecum.es/
15. Base de Datos de Costes Sanitarios eSalud (en línea) [citado 8 Feb 2007]. Barcelona: Oblikue Consukting. Disponible en: http://www.oblikue.com/bddcostes/
16. Kobelt G., Lindgren P., and Young A. Modelling the costs and effects of leflunomide in rheumatoid arthritis. Eur J Health Econom 3 (2002) 180-187
17. Smolen J.S., Kalden J.R., Scott D.L., Rozman B., Kvien T.K., Larsen A., et al., European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in activa rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 23 (1999) 259-266
18. Strand V., Tugwell P., Bombardier C., Maetzel A., Crawford B., Dorrier C., et al., Leflunomide Rheumatoid Arthritis Investigators Group. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 42 (1999) 1870-1878
19. Rubio-Terrés C., and Domínguez-Gil A. Pharmacoeconomic analysis of the treatment of rheumatoid arthritis with Leflunomide in comparison of Infliximab and Methotrexate. J Med Economics 4 (2001) 19-34
20. Braun J., Kästner P., Flaxenberg P., Währisch J., Hanke P., Demary W., et al., MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58 (2008) 73-81
21. Kose S., and Mandiracioglu A. Fear of blood/injection in healthy and unhealthy adults admitted to a teaching hospital. Int J Clin Pract 61 (2007) 453-457